ArticleClinical and experimental medicine2025
Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bioinformatics analysis and clinical validation identifyTranslational andrology and urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enfortumab vedotin (EV) has been approved for the treatment of metastatic urothelial carcinoma (mUC), either as monotherapy or in combination with immune checkpoint inhibitors, following results of recent practice-changing clinical trials. However, limited data exist regarding patients with bone metastases, leaving a critical gap in knowledge regarding the efficacy of EV in this subgroup. The study aimed to evaluate the impact of bone metastases on survival outcomes in patients with mUC treated with EV using data the ARON global real-world retrospective database, thereby addressing an important unmet clinical need. A total of 201 mUC patients with bone metastases and 377 without bone metastases who were treated with EV were analyzed from the ARON-2EV dataset. The coprimary endpoints were overall survival (OS) and progression-free survival (PFS) in mUC patients with and without bone metastases. Secondary endpoints included OS and PFS among patients with bone metastases who received versus did not receive radiotherapy or bone-targeted agents. The median OS was 11.2 months (95% CI 8.34–15.04) and 12.4 months (95% CI 10.71–15.21) in mUC patients with and without bone metastases, respectively. The median PFS was 6.0 months (95% CI 5.72–6.9) and 7.6 months (95% CI 6.6–8.24), respectively. No statistically significant difference in OS was observed between two groups (HR 1.16; 95% CI 0.9–1.5; p = 0.251), while patients without bone metastases had significantly longer PFS (HR 1.26; 95% CI 1.01–1.57; p = 0.0442). No significant survival differences were observed among patients with bone metastases based on receipt of radiotherapy or bone-targeted agents. In multivariate analyses, concomitant mixed histology and lung metastases were associated with shorter OS, while lung metastases and current smoking were associated with shorter PFS. This real-world analysis identified clinical factors associated with poorer outcomes in mUC patients with bone metastases treated with EV, including histology subtype, lung metastases, and smoking status. Further multicentric translational studies are warranted to validate these findings and to better understand the biologic mechanisms underlying limited EV efficacy in bone-metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.